TREE NEWS reports: Zai Lab reported third-quarter total revenue of $108.2 million, with product revenue of $107.6 million, down 7% year over year but up 2% sequentially. The company said the sequential improvement came mainly from broader coverage and higher penetration of core products and initial sales of xanomeline-trospium, partly offset by lower tumor-treating fields revenue.
Zai Lab Q3 revenue $108.2M, product sales down 7% YoY but up 2% QoQ
AI take
The headline weakness is mostly a year-over-year comparison, while the sequential turn and the first contribution from xanomeline-trospium suggest the commercial mix is starting to shift. That matters for a company whose valuation leans on newly launched products carrying growth once legacy lines soften. The offset from lower tumor-treating fields revenue is the detail worth watching: whether the new launch can outpace that decline is the open question.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
6m ago
Shenzhen Stock Exchange to Review XFusion IPO on Nov 12
28m ago
Global market brief: AI hardware slumps premarket, Panasonic CCL plant fire
31m ago
Qualcomm shares fall 12% in premarket trading
34m ago
Nasdaq ETFs from E Fund and GF to Halt Trading for 1 Hour on Nov 6
39m ago
Nexchip to Inject RMB 5.1B in RMB 9.1B Capital Raise for Chip Unit Jingyi
43m ago
Nexchip Plans A-Share Buyback of 500M-800M Yuan at Up to 37 Yuan/Share